Is skyrizi a biosimilar?

Is Skyrizi considered a biosimilar?

Skyrizi is not a biosimilar. It is an original (reference) biologic medicine containing risankizumab, approved for inflammatory diseases such as plaque psoriasis. Biosimilars are separate biologic products made to be highly similar to a specific reference biologic, but Skyrizi itself is the reference drug. [1]

What makes something a biosimilar vs a brand biologic like Skyrizi?

A biosimilar is a distinct product approved based on evidence that it is highly similar to an existing reference biologic in terms of structure, biological activity, and clinical performance, with some allowable differences due to manufacturing. Skyrizi is the reference biologic product, not the “follow-on” version. [1]

What to look for if you’re trying to identify a biosimilar for psoriasis treatment

If you’re searching for a biosimilar, you typically need to check whether the product name is explicitly labeled as a biosimilar and what reference biologic it compares to. Skyrizi is labeled as a branded biologic (risankizumab), not as a biosimilar. [1]

Sources:
[1] https://www.drugs.com/skyrizi.html